Sitemap > Breaking Research > Infectious Diseases
Displaying 251 - 300 of 4290 results
- Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.
- Clinical pharmacokinetics of alamifovir and its metabolites.
- Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.
- Targeting Tn5 transposase identifies human immunodeficiency virus type 1 inhibitors.
- Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.
- Synthesis and antibacterial activity of the 4-quinolone-3-carboxylic acid derivatives having a trifluoromethyl group as a novel N-1 substituent.
- Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor.
- Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential.
- Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.
- Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
- Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.
- New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1.
- Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks.
- Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.
- Respiratory syncytial virus infection in elderly and high-risk adults.
- Stage-specific antileishmanial activity of an inhibitor of SIR2 histone deacetylase.
- The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model.
- Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
- 4-Alkyl and 4,4'-dialkyl 1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione derivatives as new inhibitors of bacterial cell wall biosynthesis.
- Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.
- Biological activity assessment of a novel contraceptive antimicrobial agent.
- Activity and therapeutic potential of ORI-1001 antisense oligonucleotide on human papillomavirus replication utilizing a model of dysplastic human epithelium.
- Biaryl isoxazolinone antibacterial agents.
- Docking simulation with a purine nucleoside specific homology model of deoxycytidine kinase, a target enzyme for anticancer and antiviral therapy.
- Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
- Establishment of a screening system for selection of siRNA target sites directed against hepatitis B virus surface gene.
- Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.
- Design, construction, and characterization of a large synthetic human antibody phage display library.
- Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting.
- Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency.
- Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives.
- Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
- Mono- and bis-thiazolium salts have potent antimalarial activity.
- A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.
- KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.
- Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
- Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.
- Varicella-zoster virus ORF4 latency-associated protein is important for establishment of latency.
- HIV protease inhibitors: synthesis and activity of N-aryl-N'-hydroxyalkyl hydrazide pseudopeptides.
- Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
- Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing.
- Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence.
- Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.
- In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis.
- Antimicrobial activity and membrane selective interactions of a synthetic lipopeptide MSI-843.
- Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection.
- The 4',4'-difluoro analog of 5'-noraristeromycin: a new structural prototype for possible antiviral drug development toward orthopoxvirus and cytomegalovirus.
- Synthesis of new phorbol derivatives having ethereal side chain and evaluation of their anti-HIV activity.
- Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
- Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 Next >